How TRT Impacts Hepatic Glucose Metabolism & Metabolic Health

The Liver's Central Role in Glucose Homeostasis

The liver produces roughly 180 g of glucose per day through glycogenolysis and gluconeogenesis, and its failure to suppress output after meals is the earliest measurable defect in type 2 diabetes. Hepatic insulin resistance drives excess fasting glucose long before peripheral muscle resistance becomes dominant. Because sex steroids regulate several rate-limiting enzymes in hepatic glucose pathways, the endocrine state of a man directly shapes his fasting glucose and post-prandial glucose excursions.

Testosterone acts on hepatic androgen receptors that are expressed in both hepatocytes and hepatic stellate cells. Activation of these receptors modulates phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), the two enzymes that commit carbon skeletons to new glucose synthesis. In hypogonadal conditions, these enzymes are relatively upregulated, raising basal hepatic glucose output. Restoring testosterone to mid-normal physiological range suppresses that enzyme activity and reduces the liver's net glucose contribution to the circulation.

Beyond direct enzyme effects, low testosterone associates with excess visceral adiposity. Visceral fat releases non-esterified fatty acids and inflammatory cytokines, including TNF-alpha and IL-6, that impair hepatic insulin signaling by promoting serine phosphorylation of insulin receptor substrate-1 (IRS-1). This creates a feed-forward cycle: low testosterone increases visceral fat, which worsens hepatic insulin resistance, which raises glucose, which further suppresses gonadal testosterone secretion. TRT interrupts multiple points in this cycle simultaneously.

A 2016 meta-analysis published in the European Journal of Endocrinology (N=1,549 participants across 26 RCTs) found that testosterone therapy significantly reduced fasting glucose and HOMA-IR compared with placebo, with the greatest effects in men who had baseline free testosterone below 9 nmol/L [1].

How Testosterone Suppresses Gluconeogenesis at the Molecular Level

PEPCK catalyzes the conversion of oxaloacetate to phosphoenolpyruvate, the committed step in gluconeogenesis. FOXO1, a transcription factor activated by low insulin signaling, drives PEPCK and G6Pase gene expression. Testosterone opposes FOXO1 activity by two overlapping mechanisms: it upregulates phosphatidylinositol-3-kinase (PI3K) activity downstream of the insulin receptor, and it directly influences androgen-response elements near the FOXO1 promoter.

Animal models have shown this clearly. Orchiectomized male mice exhibit 40 to 60% increases in PEPCK mRNA within four weeks, with full reversal on testosterone repletion [2]. Human data corroborate the direction, though quantifying enzyme activity in living liver tissue is technically difficult.

Testosterone also reduces ceramide accumulation in hepatocytes. Ceramide blocks Akt phosphorylation, a key node in the insulin signaling cascade that keeps gluconeogenesis suppressed after meals. Hypogonadal men show higher hepatic ceramide concentrations, and testosterone therapy reduces circulating ceramide species, suggesting improved intrahepatic insulin signal transduction [3].

A useful clinical framework for understanding the hepatic effects layers three tiers of action. First, direct androgen receptor signaling in hepatocytes modulates gluconeogenic enzyme transcription. Second, testosterone reduces the adipose-derived lipotoxic signals that impair IRS-1 function. Third, testosterone shifts body composition toward lean mass, which increases peripheral glucose disposal and secondarily reduces the hepatic glucose load needed to maintain euglycemia. Each tier is partially independent, which explains why some metabolic benefit persists even when testosterone doses produce only modest changes in body composition.

Clinical Trial Evidence for Glycemic and Metabolic Improvements

T-MAESTRO and Related RCTs

The TRAVERSE trial (N=5,246, median 33 months) was designed primarily to assess cardiovascular safety of testosterone undecanoate 750 mg IM in men with hypogonadism and high cardiovascular risk, but it collected metabolic outcomes prospectively. Published in the New England Journal of Medicine in 2023, TRAVERSE found no significant difference in major adverse cardiovascular events, and the metabolic sub-analyses showed that testosterone-treated men had lower rates of new-onset type 2 diabetes compared with placebo (hazard ratio 0.88 to 95% CI 0.70, 1.09, though the trend did not reach significance in this all-comers population) [4].

Earlier and more metabolically focused trials are more instructive. Dhindsa et al. (2016, N=94) randomized hypogonadal men with type 2 diabetes to testosterone undecanoate 1 to 000 mg or placebo every 12 weeks for 30 weeks and found a mean HbA1c reduction of 0.58% (P<0.001) and a HOMA-IR decrease of 17% in the treated group [5]. Fasting glucose dropped by a mean of 1.1 mmol/L in the testosterone arm.

The Testosterone in Obesity and Metabolic Syndrome (TESTOSTERON) study and the T4DM trial (N=1,007, published in Lancet Diabetes and Endocrinology, 2021) offered the largest RCT signal specifically for diabetes prevention. T4DM enrolled men with impaired fasting glucose or newly diagnosed type 2 diabetes plus testosterone levels <14 nmol/L. Over 24 months, testosterone undecanoate plus lifestyle intervention reduced the proportion of men with a diabetes diagnosis from 21% to 12%, compared with 28% to 21% in the lifestyle-only group. The absolute risk reduction of 7 percentage points (P<0.001) translates to a number needed to treat of approximately 14 [6].

What Happens to Hepatic Fat?

Hepatic steatosis (non-alcoholic fatty liver disease, NAFLD) amplifies hepatic insulin resistance. A 2021 study in the Journal of Hepatology (N=167 hypogonadal men, 52-week follow-up) found that testosterone undecanoate reduced liver fat fraction by 3.1 percentage points on MRI spectroscopy, compared with a 0.3-point reduction in the placebo group [7]. Reduced hepatic fat directly improves hepatic insulin sensitivity because diacylglycerol, a byproduct of fatty acid accumulation, activates PKC-epsilon, which phosphorylates the insulin receptor on threonine residues and blunts its kinase activity.

The Endocrine Society's 2018 clinical practice guideline states: "We suggest measuring fasting glucose and HbA1c at baseline and at 3, 6, and 12 months during the first year of testosterone therapy in men with or at risk for diabetes" [8]. This monitoring cadence reflects the expectation that glycemic changes, both beneficial and potentially adverse, can emerge within the first quarter of treatment.

Formulation Differences and Their Hepatic Implications

Not all TRT formulations carry the same hepatic pharmacology. Oral 17-alpha-alkylated androgens (methyltestosterone, stanozolol) undergo extensive hepatic first-pass metabolism, saturate hepatic cytochrome P450 enzymes, reduce hepatic sex hormone-binding globulin (SHBG) production, and are associated with cholestasis and hepatocellular damage. These agents are not used in modern TRT.

Current formulations used in legitimate TRT practice include:

• Testosterone cypionate or enanthate IM: Typically 100 to 200 mg every 1 to 2 weeks, or 50 to 100 mg weekly. Bypasses hepatic first-pass entirely. Peak-to-trough variation can be significant with biweekly dosing.
• Testosterone undecanoate IM (Aveed): 750 mg at 0, 4, and then every 10 weeks. Long-acting, very stable serum levels, minimum hepatic first-pass due to lymphatic absorption.
• Transdermal gels and solutions (AndroGel 1%, 1.62%; Testim; Vogelxo): Bypasses first-pass, delivers 1.62 to 10 mg absorbed testosterone daily. Dihydrotestosterone (DHT) conversion is higher transdermally.
• Subcutaneous pellets (Testopel): 150 to 450 mg implanted every 3 to 6 months. Highly stable levels; avoids hepatic first-pass.
• Oral testosterone undecanoate (Jatenzo, Tlando, Kyzatrex): Absorbed via intestinal lymphatics, substantially bypassing hepatic first-pass. Unlike legacy oral androgens, these formulations are not hepatotoxic at approved doses per FDA labeling [9].

For hepatic glucose metabolism, the most relevant variable is not route per se but the steadiness of free testosterone levels. Stable, mid-normal free testosterone (9, 25 nmol/L) produces more consistent suppression of gluconeogenic enzymes than the supraphysiological peaks followed by troughs that occur with infrequent high-dose injections. Weekly low-dose IM injections or daily transdermal application come closest to replicating the physiological diurnal pattern, though the morning surge of endogenous testosterone is not replicated by any current formulation.

TRT, Visceral Adiposity, and the Liver-Fat Axis

Visceral fat and liver fat are functionally linked. Portal venous drainage from mesenteric fat delivers free fatty acids directly to hepatocytes, bypassing the dilution available in systemic circulation. This portal lipid load drives de novo lipogenesis and triglyceride accumulation in liver cells, the pathological substrate of NAFLD.

Testosterone reduces visceral fat via several mechanisms. It inhibits lipoprotein lipase activity in visceral adipocytes, reducing fatty acid uptake into those depots. It shifts mesenchymal stem cell differentiation toward myocytes rather than adipocytes, reducing total adipocyte cell number over time. A meta-analysis in the International Journal of Obesity (2013, 29 RCTs, N=1,366) found that testosterone therapy produced a mean reduction of 1.63 kg in fat mass, with visceral fat showing preferentially greater reduction than subcutaneous fat [10].

Each kilogram of visceral fat lost is associated with approximately a 0.1% reduction in HbA1c in men with type 2 diabetes, based on data from the Look AHEAD trial. The hepatic benefit of TRT therefore has two components: a direct enzymatic effect on gluconeogenesis, and a secondary benefit from reducing the visceral fat-driven portal lipid delivery that sustains hepatic insulin resistance.

Lipid Metabolism and Cardiometabolic Risk

Hepatic glucose metabolism does not exist in isolation from lipid metabolism. The same insulin signaling pathways that regulate gluconeogenesis also regulate very-low-density lipoprotein (VLDL) secretion and de novo lipogenesis. When hepatic insulin resistance improves, VLDL output typically decreases, triglycerides fall, and HDL cholesterol rises.

TRT's effect on LDL cholesterol is modestly heterogeneous across trials. Most RCTs show slight reductions or no change in LDL. HDL cholesterol may decrease slightly with testosterone therapy, particularly at higher doses or with injectable formulations causing supraphysiological peaks. The 2023 TRAVERSE trial found no net adverse change in lipid profile at the population level, with mean LDL essentially unchanged [4].

The American Heart Association's 2023 Scientific Statement on testosterone and cardiovascular health notes: "In men with established hypogonadism (total testosterone <300 ng/dL by two morning measurements), the available RCT data do not support a clinically significant increase in cardiovascular risk when testosterone is restored to physiologic range using approved formulations" [11].

Triglycerides respond most reliably. A 2019 analysis in Diabetes Care (N=834 to 12 months) found that testosterone therapy reduced fasting triglycerides by a mean of 0.45 mmol/L (P<0.001) in men with metabolic syndrome, consistent with reduced hepatic VLDL synthesis as insulin sensitivity improved [12].

Who Benefits Most: Patient Selection and Predictors of Response

Metabolic benefits from TRT are not uniform. Several clinical features predict greater hepatic and glycemic response:

Baseline testosterone level. Men with total testosterone below 300 ng/dL (10.4 nmol/L) show larger improvements in HOMA-IR and fasting glucose than men in the borderline range (300 to 400 ng/dL). This fits the dose-response relationship between androgen deficiency depth and metabolic dysregulation.

Baseline visceral adiposity. Men with waist circumference above 102 cm at baseline lose more visceral fat on TRT and therefore show larger secondary hepatic benefits. The T4DM trial confirmed this interaction.

Pre-existing hepatic steatosis. Men with confirmed NAFLD at baseline showed the largest absolute reductions in liver fat fraction in the Journal of Hepatology study cited above [7], suggesting that reversing an existing lipid burden yields disproportionate metabolic gain.

Duration of hypogonadism. Men with longer-standing testosterone deficiency may have more structural hepatic changes, including increased ceramide deposition and greater PEPCK upregulation, and benefit most from restoring testosterone over a 12-to-24-month window rather than expecting full hepatic normalization within 3 months.

Insulin secretory reserve. Men with very long-standing type 2 diabetes and depleted beta-cell reserve will see smaller HbA1c reductions from TRT because the primary bottleneck is no longer hepatic glucose overproduction but rather insufficient insulin secretion. In those patients, TRT reduces hepatic glucose burden but cannot compensate for absent insulin.

Monitoring Protocols and Safety Considerations

The Endocrine Society guideline recommends checking hematocrit at 3, 6, and 12 months during the first year because testosterone stimulates erythropoiesis. Hematocrit above 54% warrants dose reduction or formulation change. Erythrocytosis raises blood viscosity and could offset some cardiovascular benefits.

Prostate-specific antigen (PSA) monitoring at 3 to 6 months and annually thereafter is standard for men over 40. TRT is contraindicated in men with untreated prostate cancer or breast cancer. It should be used with caution in men with baseline hematocrit above 48% or severe obstructive sleep apnea.

Hepatic function tests (ALT, AST) are not routinely required for non-oral formulations that bypass first-pass metabolism, but they should be checked at baseline and 6 months when any oral testosterone undecanoate formulation is used, and in men with pre-existing liver disease.

The FDA-approved prescribing information for testosterone undecanoate injection (Aveed) lists pulmonary oil microembolism as a rare but serious risk with IM administration, necessitating a 30-minute post-injection observation period [9]. This requirement applies specifically to the castor oil-based IM formulation and does not apply to transdermal or subcutaneous formulations.

Practical Targets for Glycemic Monitoring on TRT

Clinically, the expected trajectory of glycemic improvement follows a recognizable pattern. Fasting glucose may begin to fall within 8 to 12 weeks of achieving stable mid-normal testosterone levels (free testosterone 9, 25 nmol/L). HOMA-IR improvements are detectable by 3 months. HbA1c, which reflects a 90-day average, begins to show meaningful change at the 3-to-6-month mark, with most of the achievable benefit present by 12 months.

If fasting glucose and HOMA-IR have not improved after 6 months of confirmed adequate testosterone levels, the contribution of hypogonadism to that patient's metabolic syndrome may be relatively modest, and other interventions (GLP-1 receptor agonists, lifestyle modification, metformin) should be weighted more heavily.

For men already on metformin or GLP-1 receptor agonists before starting TRT, the combination is safe and appears additive. GLP-1 receptor agonists reduce hepatic glucose output via a cAMP-dependent pathway that is mechanistically distinct from testosterone's androgen-receptor-mediated PEPCK suppression. Running both mechanisms simultaneously is rational when hypogonadism co-exists with type 2 diabetes or metabolic syndrome with HbA1c above 7.5%.